NTRA publication cites strong clinical validation for Signatera MRD in lymphoma
Newsdesk says NTRA published findings supporting Signatera for MRD assessment in lymphoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.